CO2022015874A2 - Inhibidores de cd38 - Google Patents

Inhibidores de cd38

Info

Publication number
CO2022015874A2
CO2022015874A2 CONC2022/0015874A CO2022015874A CO2022015874A2 CO 2022015874 A2 CO2022015874 A2 CO 2022015874A2 CO 2022015874 A CO2022015874 A CO 2022015874A CO 2022015874 A2 CO2022015874 A2 CO 2022015874A2
Authority
CO
Colombia
Prior art keywords
formula
inhibitors
treat
subject
nad
Prior art date
Application number
CONC2022/0015874A
Other languages
English (en)
Inventor
Bharat Lagu
Santosh S Kulkarni
Xinyuan Wu
Original Assignee
Mitobridge Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitobridge Inc filed Critical Mitobridge Inc
Publication of CO2022015874A2 publication Critical patent/CO2022015874A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una realización de la invención es un compuesto representado por la Fórmula I: o una sal farmacéuticamente aceptable de este. En el presente documento se definen las variables en la Fórmula I. Los compuestos de la Fórmula I son inhibidores de CD38 que se pueden utilizar para tratar una enfermedad o afección en un sujeto que se beneficia con un incremento en NAD+ o para tratar un trastorno mitocondrial en un sujeto.
CONC2022/0015874A 2020-04-07 2022-11-03 Inhibidores de cd38 CO2022015874A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202041015255 2020-04-07
PCT/US2021/025953 WO2021207186A1 (en) 2020-04-07 2021-04-06 Cd38 inhibitors

Publications (1)

Publication Number Publication Date
CO2022015874A2 true CO2022015874A2 (es) 2022-11-18

Family

ID=75690672

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0015874A CO2022015874A2 (es) 2020-04-07 2022-11-03 Inhibidores de cd38

Country Status (14)

Country Link
US (1) US20230158024A1 (es)
EP (1) EP4132919A1 (es)
JP (1) JP2023521694A (es)
KR (1) KR20230051425A (es)
CN (1) CN115697985A (es)
AR (1) AR121759A1 (es)
AU (1) AU2021251753A1 (es)
BR (1) BR112022020291A2 (es)
CA (1) CA3179589A1 (es)
CO (1) CO2022015874A2 (es)
IL (1) IL297128A (es)
MX (1) MX2022012638A (es)
TW (1) TW202204331A (es)
WO (1) WO2021207186A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022542396A (ja) 2019-07-31 2022-10-03 ライボン・セラピューティクス・インコーポレイテッド Ｃｄ３８の阻害剤としてのヘテロ二環式アミド
AR124718A1 (es) 2021-01-29 2023-04-26 Ribon Therapeutics Inc Quinolinas y azaquinolinas como inhibidores de cd38
AU2022310682A1 (en) * 2021-07-12 2024-01-25 Cytokinetics, Inc. Cd38 modulators and methods of use thereof
CN118317955A (zh) * 2021-11-09 2024-07-09 塞里文斯股份有限公司 作为cd38抑制剂的n-(4-氨基环己基)嘧啶-4-甲酰胺
WO2023098699A1 (en) * 2021-12-01 2023-06-08 Nanjing Immunophage Biotech Co., Ltd Compounds and their uses as cd38 inhibitors
WO2023235880A1 (en) * 2022-06-02 2023-12-07 Aeovian Pharmaceuticals, Inc. Cd38 modulators and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170090478A (ko) * 2014-12-03 2017-08-07 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 Cd38 억제제 및 치료 방법
WO2017079195A1 (en) 2015-11-02 2017-05-11 Mitobridge, Inc. Nicotinamide riboside and nicotinamide mononucleotide derivatives for use in the treatments of mitochondrial-related diseases
US11304946B2 (en) * 2017-11-21 2022-04-19 Bayer Aktiengesellschaft 2-hetarylpyrimidine-4-carboxamides as aryl hydrocarbon receptor antagonists

Also Published As

Publication number Publication date
MX2022012638A (es) 2023-01-04
AR121759A1 (es) 2022-07-06
CA3179589A1 (en) 2021-10-14
CN115697985A (zh) 2023-02-03
WO2021207186A1 (en) 2021-10-14
JP2023521694A (ja) 2023-05-25
EP4132919A1 (en) 2023-02-15
AU2021251753A1 (en) 2022-12-08
TW202204331A (zh) 2022-02-01
US20230158024A1 (en) 2023-05-25
KR20230051425A (ko) 2023-04-18
BR112022020291A2 (pt) 2022-12-06
IL297128A (en) 2022-12-01

Similar Documents

Publication Publication Date Title
CO2022015874A2 (es) Inhibidores de cd38
AR121047A1 (es) Inhibidores de map4k1
NI201800093A (es) Inhibidores de mcl1 macrocíclicos para tratar el cáncer
AR116604A1 (es) Inhibidores de kras g12c
CL2020001752A1 (es) Derivado de oxi-fluoropiperidina como inhibidor de quinasa.
CO2020007156A2 (es) Derivado de amino-metil piperidina como inhibidor de quinasa
AR111304A1 (es) Métodos para sintetizar un inhibidor de mcl-1
CO2022002804A2 (es) Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos
CR20160287A (es) Inhibidores de syk
CL2021001461A1 (es) Moduladores de trex1
CO2024001367A2 (es) Compuestos antivirales
BR112020016020A8 (pt) Inibidor de atr e aplicação do mesmo
AR126251A1 (es) Inhibidores de cdk2
CL2019001041A1 (es) Compuestos terapéuticos y métodos para utilizarlos.
CO2021014210A2 (es) Compuestos de pirrol
MX2020004930A (es) Compuestos de biarilo sustituido novedosos como inhibidores de indolamina 2,3-dioxigenasa (ido).
ECSP24003566A (es) Pirimidinil-pirazoles sustituidos como inhibidores de cdk2
ECSP22091313A (es) Compuestos heterocíclicos como anthelmínticos
CL2023001339A1 (es) Un inhibidor de magl.
UY37641A (es) Compuestos de isoxazol carboxamida y usos de los mismos
CL2021003139A1 (es) Compuestos tricíclicos
CO2021010415A2 (es) Inhibidor jak y método de preparación del mismo
CL2021001640A1 (es) Formas de sal y cristalinas de un compuesto orgánico y composiciones farmacéuticas del mismo
ECSP23088732A (es) Moduladores de trex1
CL2019002025A1 (es) Derivados de pirrolotriazina como inhibidor de cinasas.